These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29174186)

  • 1. Safety and efficacy of eribulin for "real-world" older patients with metastatic breast cancer.
    de Nonneville A; Sabatier R; Gonçalves A; Extra JM; Tarpin C; Launay S; Tassy L; Viens P; Rousseau F
    J Geriatr Oncol; 2018 May; 9(3):281-283. PubMed ID: 29174186
    [No Abstract]   [Full Text] [Related]  

  • 2. Feasibility of Eribulin Mesylate in older patients with locally advanced or metastatic breast cancer: A post-hoc analysis of the ESEMPiO study.
    Barni S; Livraghi L; Gravina A; Martella F; D'Onofrio L; Morritti M; Michelotti A; Vici P; Mentuccia L; Porcu L; Orditura M; Puglisi F;
    J Geriatr Oncol; 2019 Nov; 10(6):990-993. PubMed ID: 31097340
    [No Abstract]   [Full Text] [Related]  

  • 3. Eribulin efficacy based on type of metastatic site: a real-life study in heavily pretreated metastatic breast cancer.
    Prestifilippo A; Grippaldi D; Blanco G; Memeo L; Puliafito I; Giuffrida D
    Future Oncol; 2017 Apr; 13(11s):5-10. PubMed ID: 28481186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anti-tumor mechanism and clinical efficacy of Eribulin (Halaven®), a new microtubulin inhibitor approved for treatment of metastatic breast cancer].
    Koyama N; Tokunaga T; Ogasawara W; Murakami M; Yamashita Y
    Nihon Yakurigaku Zasshi; 2011 Nov; 138(5):209-17. PubMed ID: 22075465
    [No Abstract]   [Full Text] [Related]  

  • 5. Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE.
    Leo S; Arnoldi E; Repetto L; Coccorullo Z; Cinieri S; Fedele P; Cazzaniga M; Lorusso V; Latorre A; Campanella G; Ciccarese M; Accettura C; Pisconti S; Rinaldi A; Brunetti C; Raffaele M; Coltelli L; Spazzapan S; Fratino L; Petrucelli L; Biganzoli L
    Oncologist; 2019 Jun; 24(6):e232-e240. PubMed ID: 30413667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan.
    Rau KM; Ou-Yang F; Chao TC; Kuo YL; Cheng TF; Chao TY; Chen DR; Tzeng YD; Wang BW; Liu CY; Hu MH; Lu YC; Ou WJ; Kuo CH; Chuang CH; Kan JY; Chen FM; Hou MF
    Breast Cancer Res Treat; 2018 Aug; 170(3):583-591. PubMed ID: 29623575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety of eribulin for the treatment of metastatic breast cancer.
    Perez-Garcia JM; Cortes J
    Expert Opin Drug Saf; 2019 May; 18(5):347-355. PubMed ID: 31107111
    [No Abstract]   [Full Text] [Related]  

  • 8. Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective study.
    Kobayashi T; Tomomatsu J; Fukada I; Shibayama T; Teruya N; Ito Y; Iwase T; Ohno S; Takahashi S
    BMC Cancer; 2016 Jul; 16():404. PubMed ID: 27389013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer.
    O'Shaughnessy J; Kaklamani V; Kalinsky K
    Future Oncol; 2019 May; 15(14):1641-1653. PubMed ID: 30892083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eribulin mesylate in advanced breast cancer: retrospective review of a single institute experience.
    Martella F; Bacci C; Giordano C; Montagnani F; Gelain E; Rabatti L; Fioretto L
    Future Oncol; 2015; 11(15 Suppl):31-6. PubMed ID: 26235263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eribulin Suppresses New Metastases in Patients With Metastatic Breast Cancer.
    Fujii T; Tokuda S; Nakazawa Y; Kurozumi S; Obayashi S; Yajima R; Shirabe K
    In Vivo; 2020; 34(2):917-921. PubMed ID: 32111804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance.
    Inoue K; Saito T; Okubo K; Kimizuka K; Yamada H; Sakurai T; Ishizuna K; Hata S; Kai T; Kurosumi M
    Breast Cancer Res Treat; 2016 Jun; 157(2):295-305. PubMed ID: 27125669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective analysis of the efficacy and safety of eribulin therapy for metastatic breast cancer in daily practice.
    Tanaka T; Ueno M; Nakashima Y; Chinen S; Sato E; Masaki M; Mogi A; Sasaki H; Tamura K; Takamatsu Y
    Thorac Cancer; 2017 Sep; 8(5):523-529. PubMed ID: 28741868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to eribulin in a difficult-to-treat, heavily pretreated breast cancer patient: a case report.
    Leo L; Caputo F; Sarno AD; Garofano T; Andreozzi F; Massaro MG; Montesarchio V
    Future Oncol; 2015; 11(15 Suppl):27-30. PubMed ID: 26235262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in therapy: eribulin improves survival for metastatic breast cancer.
    Morris PG
    Anticancer Drugs; 2010 Nov; 21(10):885-9. PubMed ID: 20838209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of eribulin in taxane-refractory patients in the 'real world'.
    Lorusso V; Cinieri S; Latorre A; Porcu L; Del Mastro L; Puglisi F; Barni S
    Future Oncol; 2017 May; 13(11):971-978. PubMed ID: 28326833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eribulin rapidly reduces the aggressiveness of second primary breast cancer: a case report.
    Falco I; Stragliotto S
    Future Oncol; 2017 Apr; 13(11s):51-54. PubMed ID: 28481187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eribulin across multiple lines of chemotherapy: a retrospective study on quality of life and efficacy in metastatic breast cancer patients.
    Quaquarini E; Sottotetti F; D'Ambrosio D; Malovini A; Morganti S; Marinello A; Pavesi L; Frascaroli M
    Future Oncol; 2017 Apr; 13(11s):11-23. PubMed ID: 28481185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY).
    Ohtani S; Nakayama T; Yoshinami T; Watanabe KI; Hara F; Sagara Y; Kawaguchi H; Higaki K; Matsunami N; Hasegawa Y; Takahashi M; Mizutani M; Morimoto T; Sato M; Itoh M; Morita S; Masuda N
    Breast Cancer; 2018 Jul; 25(4):438-446. PubMed ID: 29435730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.
    Park YH; Kim TY; Im YH; Lee KS; Park IH; Sohn J; Lee SH; Im SA; Kim JH; Kim SH; Lee SJ; Koh SJ; Lee KH; Choi YJ; Cho EK; Lee S; Kang SY; Seo JH; Kim SB; Jung KH
    Cancer Res Treat; 2017 Apr; 49(2):423-429. PubMed ID: 27488876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.